Critical Contrast: Praxis Precision Medicines (NASDAQ:PRAX) versus Foghorn Therapeutics (NASDAQ:FHTX)

Praxis Precision Medicines (NASDAQ:PRAX) and Foghorn Therapeutics (NASDAQ:FHTX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Volatility and Risk

Praxis Precision Medicines has a beta of 2.85, indicating that its stock price is 185% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.22, indicating that its stock price is 222% more volatile than the S&P 500.

Profitability

This table compares Praxis Precision Medicines and Foghorn Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-29.41%	-28.19%
Foghorn Therapeutics	8.40%	-13.46%	4.63%

Institutional & Insider Ownership

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Praxis Precision Medicines and Foghorn Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55 million	1,061.64	-$303.27 million	($12.80)	-25.37
Foghorn Therapeutics	$30.91 million	3.98	-$74.28 million	$0.07	29.29

Foghorn Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Praxis Precision Medicines and Foghorn Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2	1	16	3	2.91
Foghorn Therapeutics	1	6	4	0	2.27

Praxis Precision Medicines presently has a consensus price target of $631.68, suggesting a potential upside of 94.51%. Foghorn Therapeutics has a consensus price target of $6.14, suggesting a potential upside of 199.65%. Given Foghorn Therapeutics’ higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than Praxis Precision Medicines.

Summary

Foghorn Therapeutics beats Praxis Precision Medicines on 10 of the 15 factors compared between the two stocks.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.

About Foghorn Therapeutics

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for cancer. Its research centers on chromatin regulatory systems, which help control how genes are expressed and can contribute to disease when disrupted. The company’s Gene Traffic Control platform is designed to identify drug targets within these systems. Foghorn has developed investigational programs targeting chromatin regulators, including components of the BAF complex; its candidates remain in development and are not approved medicines.